|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
LT3421603T
(lt)
|
2009-05-02 |
2022-01-10 |
Genzyme Corporation |
Genų terapija, skirta neurodegeneraciniams sutrikimams
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
US9546369B2
(en)
|
2010-04-23 |
2017-01-17 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
DK2561073T3
(en)
|
2010-04-23 |
2016-12-12 |
Univ Massachusetts |
Aav vectors targeted to central nervous system and methods of use thereof
|
|
WO2011133901A2
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
ES2661680T3
(es)
|
2011-04-21 |
2018-04-03 |
University Of Massachusetts |
Composiciones basadas en VAAr y métodos para tratar deficiencias de alfa-1 anti-tripsina
|
|
KR20220056884A
(ko)
|
2011-04-22 |
2022-05-06 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 지니는 아데노-관련 바이러스 및 이의 사용 방법
|
|
CN115120746A
(zh)
*
|
2013-05-15 |
2022-09-30 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
|
ES2897508T3
(es)
|
2013-05-31 |
2022-03-01 |
Univ California |
Variantes de virus adenoasociados y métodos de uso de las mismas
|
|
US9585971B2
(en)
|
2013-09-13 |
2017-03-07 |
California Institute Of Technology |
Recombinant AAV capsid protein
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
KR102288849B1
(ko)
|
2014-03-17 |
2021-08-12 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
|
|
EP3750907A3
(en)
|
2014-03-18 |
2021-04-28 |
University of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
|
SI3137497T2
(sl)
|
2014-05-02 |
2025-07-31 |
Genzyme Corporation |
Vektorji AAV za gensko terapijo mrežnice in centralnega živčnega sistema
|
|
EP3143146B1
(en)
*
|
2014-05-14 |
2020-05-20 |
Esteve Pharmaceuticals, S.A. |
Adenoassociated virus vectors for the treatment of lysosomal storage disorders
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
JP6842410B2
(ja)
|
2014-10-03 |
2021-03-17 |
ユニバーシティ オブ マサチューセッツ |
新規の高効率ライブラリーにより同定されるａａｖベクター
|
|
JP7023108B2
(ja)
|
2014-10-21 |
2022-02-21 |
ユニバーシティ オブ マサチューセッツ |
組み換えａａｖバリアントおよびその使用
|
|
EP3256588A2
(en)
|
2015-02-10 |
2017-12-20 |
Genzyme Corporation |
VARIANT RNAi
|
|
EP3256594B1
(en)
*
|
2015-02-10 |
2021-10-20 |
Genzyme Corporation |
Enhanced delivery of viral particles to the striatum and cortex
|
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
BR112017018846A2
(pt)
|
2015-03-02 |
2018-07-31 |
Adverum Biotechnologies, Inc. |
composições e métodos para entrega intravítrea de polinucleotídeos a cones retinianos.
|
|
EP3719134B1
(en)
|
2015-03-11 |
2023-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Rp2 vectors for treating x-linked retinitis pigmentosa
|
|
ES2860712T3
(es)
|
2015-03-24 |
2021-10-05 |
Univ California |
Variantes de virus adenoasociados y métodos de uso de las mismas
|
|
CA2981616C
(en)
|
2015-04-06 |
2025-06-17 |
Arcellx, Inc. |
De novo binding domain polypeptides and their uses
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
WO2016164642A1
(en)
|
2015-04-08 |
2016-10-13 |
The United States Of America, As Represented By The Secretary Of Health And Human Services |
Viral gene therapy as treatment for cholesterol storage disease or disorder
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
EP3831842A1
(en)
|
2015-09-28 |
2021-06-09 |
The University of North Carolina at Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
|
EP3364996B1
(en)
|
2015-10-22 |
2021-08-25 |
University of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
|
BR112018011711A2
(pt)
*
|
2015-12-11 |
2018-12-04 |
California Inst Of Techn |
peptídeos de direcionamento para direcionar virus adeno-associados (aav)
|
|
KR102833376B1
(ko)
*
|
2015-12-15 |
2025-07-11 |
젠자임 코포레이션 |
뮤코지질증 ii형을 치료하기 위한 아데노-관련 바이러스 벡터
|
|
US11826433B2
(en)
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
US20190071681A1
(en)
*
|
2016-02-26 |
2019-03-07 |
University Of Florida Research Foundation, Incorporated |
Aav heparin mutants that display significantly improved eye and brain transduction
|
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
CN107287238B
(zh)
*
|
2016-04-11 |
2020-10-16 |
厦门继景生物技术有限责任公司 |
一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物
|
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
|
RU2764587C2
(ru)
*
|
2016-05-18 |
2022-01-18 |
Вояджер Терапьютикс, Инк. |
Способы и композиции для лечения хореи гентингтона
|
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
AU2017292010B2
(en)
*
|
2016-07-08 |
2023-07-27 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving RDH12
|
|
EP3485005A1
(en)
|
2016-07-12 |
2019-05-22 |
The University Of Manchester |
Gene therapy
|
|
KR102511979B1
(ko)
|
2016-07-29 |
2023-03-20 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 갖는 아데노-관련된 바이러스 비리온 및 이의 사용 방법
|
|
WO2018035213A1
(en)
*
|
2016-08-16 |
2018-02-22 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
|
CA3034089A1
(en)
*
|
2016-08-18 |
2018-02-22 |
The Regents Of The University Of California |
Crispr-cas genome engineering via a modular aav delivery system
|
|
CA3073137A1
(en)
*
|
2016-08-19 |
2018-02-22 |
Jeffrey S. Bartlett |
Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
|
|
WO2018035457A1
(en)
*
|
2016-08-19 |
2018-02-22 |
Calimmune, Inc. |
Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
EP3519431A1
(en)
|
2016-09-28 |
2019-08-07 |
Cohbar Inc. |
Therapeutic mots-c related peptides
|
|
WO2018064624A1
(en)
|
2016-09-29 |
2018-04-05 |
University Of Florida Research Foundation, Incorporated |
Aavrh.10 variants with host antibody escape capabilities and altered tissue targeting properties
|
|
JP7577291B6
(ja)
|
2016-10-13 |
2024-11-26 |
ユニバーシティ オブ マサチューセッツ |
Ａａｖカプシド設計
|
|
EP3528785A4
(en)
|
2016-10-19 |
2020-12-02 |
Adverum Biotechnologies, Inc. |
MODIFIED AAV CASPIDS AND USES THEREOF
|
|
KR20190088561A
(ko)
|
2016-12-07 |
2019-07-26 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
인터류킨-1 수용체 길항제(IL-1RA) cDNA
|
|
WO2018145009A1
(en)
*
|
2017-02-06 |
2018-08-09 |
University Of Tennessee Research Foundation |
Dna-zyme based methods & compositions for treating huntington's disease
|
|
WO2018156892A1
(en)
|
2017-02-23 |
2018-08-30 |
Adrx, Inc. |
Peptide inhibitors of transcription factor aggregation
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
WO2018191450A2
(en)
|
2017-04-14 |
2018-10-18 |
National Taiwan University Hospital |
Gene therapy for aadc deficiency
|
|
WO2018200419A1
(en)
*
|
2017-04-23 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Viral vectors comprising engineered aav capsids and compositions containing the same
|
|
SG11201909868YA
(en)
*
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
US11859179B2
(en)
|
2017-05-09 |
2024-01-02 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (ALS)
|
|
CA3061968A1
(en)
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
|
|
CA3066077A1
(en)
|
2017-06-07 |
2018-12-13 |
Adrx, Inc. |
Tau aggregation inhibitors
|
|
KR20250023600A
(ko)
|
2017-06-30 |
2025-02-18 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법
|
|
AU2018311069A1
(en)
|
2017-08-03 |
2020-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
CA3059995A1
(en)
|
2017-08-28 |
2019-03-07 |
The Regents Of The University Of California |
Adeno-associated virus capsid variants and methods of use thereof
|
|
US11739330B2
(en)
|
2017-09-22 |
2023-08-29 |
University Of Massachusetts |
SOD1 dual expression vectors and uses thereof
|
|
UY37897A
(es)
|
2017-09-22 |
2019-04-30 |
Genzyme Corp |
ARNi VARIANTE
|
|
WO2019060649A1
(en)
*
|
2017-09-22 |
2019-03-28 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
|
|
CN111601884A
(zh)
*
|
2017-10-16 |
2020-08-28 |
维格内罗有限责任公司 |
Aav载体
|
|
KR102763312B1
(ko)
|
2017-10-20 |
2025-02-07 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
치료적으로 유효한 양의 재조합 aav9- 유도 벡터의 망막하 전달을 포함하는 대상체의 원추 광수용체 내 관심의 폴리뉴클레오티드를 발현하는 방법
|
|
US11464803B2
(en)
|
2017-11-14 |
2022-10-11 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
CA3082410A1
(en)
|
2017-11-14 |
2019-05-23 |
Arcellx, Inc. |
Multifunctional immune cell therapies
|
|
MY204271A
(en)
*
|
2017-11-15 |
2024-08-20 |
Ucl Business Ltd |
Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
|
|
KR20200084028A
(ko)
*
|
2017-11-15 |
2020-07-09 |
프리드리히 미셔 인스티튜트 포 바이오메디칼 리서치 |
영장류 망막 색소 상피 세포-특이적 프로모터
|
|
CN111727251B
(zh)
|
2017-11-21 |
2024-09-20 |
克里斯珀医疗股份公司 |
用于治疗常染色体显性色素性视网膜炎的材料和方法
|
|
CN108085316B
(zh)
*
|
2017-12-25 |
2021-02-09 |
中国人民解放军第四军医大学 |
一种通过抑制微小核糖核酸来促进小鼠视网膜前体细胞体外扩增的方法
|
|
EP3768327A4
(en)
*
|
2018-03-23 |
2022-04-13 |
The Trustees of Columbia University in the City of New York |
GENE EDITING FOR AUTOSOMAL DOMINANT DISEASES
|
|
JP2021519581A
(ja)
|
2018-04-03 |
2021-08-12 |
ストライドバイオ，インコーポレイテッド |
抗体を回避するウイルスベクター
|
|
KR20210006358A
(ko)
|
2018-04-03 |
2021-01-18 |
스트라이드바이오 인코포레이티드 |
안 조직을 표적으로 하기 위한 바이러스 벡터
|
|
CN112272672A
(zh)
|
2018-04-03 |
2021-01-26 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
MX2020011386A
(es)
|
2018-04-27 |
2021-01-29 |
Spacecraft Seven Llc |
Terapia genica para la degeneracion del snc.
|
|
EP3793616A1
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
JP2021523914A
(ja)
|
2018-05-15 |
2021-09-09 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
パーキンソン病を治療するための組成物および方法
|
|
US12338267B2
(en)
|
2018-05-15 |
2025-06-24 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
WO2019222444A2
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
CN118480544A
(zh)
*
|
2018-06-01 |
2024-08-13 |
佛罗里达大学研究基金会有限公司 |
用于治疗显性视网膜色素变性的组合物和方法
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
PH12021550254A1
(en)
|
2018-08-03 |
2023-02-06 |
Genzyme Corp |
Variant rnai against alpha-synuclein
|
|
CN109022487A
(zh)
*
|
2018-08-15 |
2018-12-18 |
上海市第人民医院 |
一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
|
|
JP7624724B2
(ja)
|
2018-09-26 |
2025-01-31 |
カリフォルニア インスティテュート オブ テクノロジー |
標的遺伝子療法のためのアデノ随伴ウイルス組成物
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
WO2020077091A1
(en)
*
|
2018-10-10 |
2020-04-16 |
Wisconsin Alumni Research Foundation |
Kir 7.1 gene therapy vectors and methods of using the same
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
US20210348135A1
(en)
*
|
2018-10-12 |
2021-11-11 |
Genzyme Corporation |
Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
WO2020099956A1
(en)
*
|
2018-11-13 |
2020-05-22 |
Indian Institute Of Technology Kanpur |
A process for producing a plurality of sumoylation target-site modified aav vector and product thereof
|
|
JP7558167B2
(ja)
|
2018-12-03 |
2024-09-30 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
オリゴベンズアミド類似体およびがん処置におけるそれらの使用
|
|
US20220089670A1
(en)
*
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
DK3906066T5
(da)
*
|
2019-01-04 |
2024-08-05 |
Ultragenyx Pharmaceutical Inc |
Geneterapikonstruktioner til behandling af wilsons sygdom
|
|
SG11202107645RA
(en)
|
2019-01-18 |
2021-08-30 |
Voyager Therapeutics Inc |
Methods and systems for producing aav particles
|
|
EP3914229A4
(en)
*
|
2019-01-23 |
2022-11-02 |
University of Florida Research Foundation, Incorporated |
Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
|
|
JP2022518814A
(ja)
|
2019-01-28 |
2022-03-16 |
コーバー、インコーポレイテッド |
治療用ペプチド
|
|
PT3850089T
(pt)
|
2019-02-04 |
2024-01-24 |
Freeline Therapeutics Ltd |
Polinucleótidos
|
|
KR20210135267A
(ko)
*
|
2019-03-04 |
2021-11-12 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
반대측 눈에 대한 aav 유전자 요법의 순차적 유리체내 투여
|
|
EP3935078A4
(en)
|
2019-03-04 |
2022-12-21 |
Duke University |
COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF RETINOPATHIES
|
|
US20220175961A1
(en)
*
|
2019-03-08 |
2022-06-09 |
Universite Paris-Saclay |
Improved therapeutic method for rare ocular diseases by gene replacement
|
|
AR118465A1
(es)
|
2019-03-21 |
2021-10-06 |
Stridebio Inc |
Vectores de virus adenoasociados recombinantes
|
|
CN114026115A
(zh)
*
|
2019-04-10 |
2022-02-08 |
普利维尔治疗公司 |
用于溶酶体病症的基因疗法
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
CA3139852A1
(en)
*
|
2019-05-13 |
2020-11-19 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Polymer-based implant for retinal therapy and methods of making and using the same
|
|
US20220226507A1
(en)
*
|
2019-05-17 |
2022-07-21 |
Research Institute At Nationwide Children's Hospital |
Optimized gene therapy targeting retinal cells
|
|
CN114502575A
(zh)
*
|
2019-06-10 |
2022-05-13 |
同源药物公司 |
用于arsa基因转移的腺相关病毒组合物和其使用方法
|
|
CA3144986A1
(en)
*
|
2019-06-27 |
2020-12-30 |
University Of Florida Research Foundation, Incorporated |
Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid
|
|
US11446084B2
(en)
|
2019-07-12 |
2022-09-20 |
Neuralink Corp. |
Laser drilling of pia mater
|
|
US20220267797A1
(en)
*
|
2019-07-15 |
2022-08-25 |
Meiragtx Uk Ii Limited |
Modified AAV Capsid Proteins for Treatment of Arthritic Disease
|
|
CN110295151A
(zh)
*
|
2019-07-17 |
2019-10-01 |
博鑫仪器(天津)有限公司 |
一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
|
|
WO2021041324A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Duke University |
Compositions and methods for the treatment of pathological pain and itch
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
US20220324921A1
(en)
*
|
2019-09-03 |
2022-10-13 |
University Of Cincinnati |
Methods and compositions for the treatment of als
|
|
AU2020363984A1
(en)
*
|
2019-10-10 |
2022-04-28 |
Solid Biosciences Inc. |
Modified aav capsids and uses thereof
|
|
US11905523B2
(en)
|
2019-10-17 |
2024-02-20 |
Ginkgo Bioworks, Inc. |
Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
|
|
CA3155154A1
(en)
*
|
2019-10-23 |
2021-04-29 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
EP4055030A4
(en)
*
|
2019-11-08 |
2024-05-22 |
President And Fellows Of Harvard College |
VIRAL CAPSID POLYPEPTIDES
|
|
CN113025618B
(zh)
*
|
2019-12-24 |
2024-02-06 |
朗信启昇(苏州)生物制药有限公司 |
一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
|
|
BR112022014852A2
(pt)
|
2020-01-29 |
2022-10-11 |
Genzyme Corp |
Proteínas modificadas do capsídeo viral adenoassociado para terapia gênica ocular e métodos de uso das mesmas
|
|
EP4100123A4
(en)
*
|
2020-02-07 |
2024-03-27 |
The Trustees of Columbia University in the City of New York |
Reprogramming the metabolome to delay onset or treat neurodegeneration
|
|
CN115210248A
(zh)
*
|
2020-02-18 |
2022-10-18 |
北卡罗来纳大学查佩尔希尔分校 |
Aav衣壳-启动子相互作用和细胞选择性基因表达
|
|
WO2021173984A2
(en)
*
|
2020-02-28 |
2021-09-02 |
University Of Massachusetts |
Oligonucleotides for prnp modulation
|
|
BR112022017970A2
(pt)
*
|
2020-03-11 |
2022-10-25 |
Massachusetts Eye & Ear Infirmary |
Terapia gênica para degeneração da retina associada ao nmnat1
|
|
JP2023529054A
(ja)
*
|
2020-03-31 |
2023-07-07 |
ユニバーシティ オブ マサチューセッツ |
Ａａｖキャプシドバリアントおよびその使用
|
|
JP2023523573A
(ja)
*
|
2020-04-14 |
2023-06-06 |
ジェネトン |
酸性セラミダーゼ欠乏症を処置するためのベクター
|
|
WO2021211753A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
MX2022014256A
(es)
|
2020-05-13 |
2023-01-11 |
Voyager Therapeutics Inc |
Redirección del tropismo de las cápsides de aav.
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
JP2023529503A
(ja)
*
|
2020-06-13 |
2023-07-10 |
オクロジェネクス インコーポレイテッド |
網膜症のためのａａｖ媒介性遺伝子導入
|
|
CN113952472A
(zh)
*
|
2020-07-21 |
2022-01-21 |
英斯培瑞有限公司 |
用于治疗眼部疾病的组合物和方法
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
MX2023000815A
(es)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composiciones y metodos para el tratamiento de trastornos neurologicos relacionados con la deficiencia de glucosilceramidasa beta.
|
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
WO2022031756A1
(en)
|
2020-08-05 |
2022-02-10 |
Spacecraft Seven, Llc |
Csrp3 (cysteine and glycine rich protein 3) gene therapy
|
|
MX2023001615A
(es)
|
2020-08-07 |
2023-03-08 |
Spacecraft Seven Llc |
Genoterapia con placofilina-2 (pkp2) mediante el uso de vector de aav.
|
|
IL300728A
(en)
*
|
2020-08-19 |
2023-04-01 |
Sarepta Therapeutics Inc |
Adeno-associated virus vectors for the treatment of Rett syndrome
|
|
CA3191543A1
(en)
*
|
2020-09-04 |
2022-03-10 |
Lei Cao |
Novel engineered capsid serotype of recombinant adeno-associated viral vector with enhanced transduction efficiency and widespread distribution in the brain
|
|
WO2022087238A1
(en)
*
|
2020-10-21 |
2022-04-28 |
Wisconsin Alumni Research Foundation |
Anti-apoptotic vector and method of using the same
|
|
US20220160825A1
(en)
*
|
2020-11-25 |
2022-05-26 |
The Penn State Research Foundation |
Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion
|
|
CN117157091A
(zh)
*
|
2021-02-22 |
2023-12-01 |
科罗拉多大学董事会法人团体 |
基于病毒载体的眼部病症的基因治疗
|
|
CN115044614B
(zh)
*
|
2021-03-09 |
2023-10-20 |
上海目镜生物医药科技有限公司 |
一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
|
|
US20240218396A1
(en)
*
|
2021-04-26 |
2024-07-04 |
Grace Science, Llc |
Compositions and methods for treating ngyl1 deficiency
|
|
AU2022340595A1
(en)
*
|
2021-09-06 |
2024-04-18 |
Huidagene Therapeutics (Singapore) Pte. Ltd. |
Treatment of rpe65-associated eye diseases and disorders
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
KR20240110849A
(ko)
|
2021-11-29 |
2024-07-16 |
상하이 레제네리드 테라피즈 컴퍼니 리미티드 |
Aadc/gdnf 폴리뉴클레오티드 및 이의 파킨슨병 치료에 있어서의 용도
|
|
CA3244192A1
(en)
|
2022-02-21 |
2025-01-22 |
Shanghai Regenelead Therapies Co., Ltd |
VEGF-BINDING MOLECULE AND ITS PHARMACEUTICAL USE
|
|
WO2023183623A1
(en)
*
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
CN120866361A
(zh)
*
|
2022-04-19 |
2025-10-31 |
上海天泽云泰生物医药有限公司 |
用于治疗神经退行性障碍的重组aav载体
|
|
CN119451703A
(zh)
*
|
2022-04-25 |
2025-02-14 |
迈特勒公司 |
髓鞘病症的治疗
|
|
US20250262248A1
(en)
|
2022-04-25 |
2025-08-21 |
Cell Cure Neurosciences, Ltd. |
Methods and compositions for treating vision loss
|
|
CN118974284A
(zh)
|
2022-05-06 |
2024-11-15 |
诺华股份有限公司 |
新型重组aav vp2融合多肽
|
|
WO2023240220A1
(en)
*
|
2022-06-09 |
2023-12-14 |
The University Of North Carolina At Chapel Hill |
Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
EP4551253A1
(en)
|
2022-07-08 |
2025-05-14 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes
|
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
|
EP4555097A2
(en)
*
|
2022-07-12 |
2025-05-21 |
The Research Institute at Nationwide Children's Hospital |
Adeno-associated virus gene therapy products and methods
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2024218311A1
(fr)
|
2023-04-21 |
2024-10-24 |
Pulsesight Therapeutics |
Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
|
|
GB202306952D0
(en)
*
|
2023-05-11 |
2023-06-28 |
Neurochase Innovations Ltd |
Method
|
|
US20250197862A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
ARTIFICIAL microRNAs TARGETING TAU
|
|
WO2025160452A1
(en)
|
2024-01-25 |
2025-07-31 |
Genzyme Corporation |
Methods for fus-based delivery of viral particles to the brain
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|